@article {12283,
	title = {Targeting Notch in oncology: the path forward.},
	journal = {Nat Rev Drug Discov},
	volume = {20},
	year = {2021},
	month = {2021 02},
	pages = {125-144},
	abstract = {<p>Notch signalling is involved in many aspects of cancer biology, including angiogenesis, tumour immunity and the maintenance of cancer stem-like cells. In addition, Notch can function as an oncogene and a tumour suppressor in different cancers and in different cell populations within the same tumour. Despite promising preclinical results and early-phase clinical trials, the goal of developing safe, effective, tumour-selective Notch-targeting agents for clinical use remains elusive. However, our continually improving understanding of Notch signalling in specific cancers, individual cancer cases and different cell populations, as well as crosstalk between pathways, is aiding the discovery and development of novel investigational Notch-targeted therapeutics.</p>
},
	keywords = {Animals, Antineoplastic Agents, Drug Delivery Systems, Humans, Immunotherapy, Neoplasms, Neoplastic Stem Cells, Receptors, Notch, Signal Transduction},
	issn = {1474-1784},
	doi = {10.1038/s41573-020-00091-3},
	author = {Majumder, Samarpan and Crabtree, Judy S and Golde, Todd E and Minter, Lisa M and Osborne, Barbara A and Miele, Lucio}
}
